ARQT — Arcutis Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $3.38bn
- $3.26bn
- $376.07m
Brief: Arcutis Says New Data Shows Zoryve® (Roflumilast) Cream 0.15% Provided Consistent Improvement Of Atopic Dermatitis In Individuals With Diverse Skin Types
Brief: FDA Accepts Arcutis’ Supplemental New Drug Application For Zoryve
Brief: Arcutis Completes Enrollment Of Phase 1B Alopecia Areata Study Evaluating ARQ-255
Arcutis climbs on positive trial results for skin disease treatment
Brief: Arcutis Announces Positive Long-Term Results Of Roflumilast Cream
Arcutis Biotherapeutics Inc reports results for the quarter ended in June - Earnings Summary
Arcutis Biotherapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview
Arcutis Biotherapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Arcutis Submits Supplemental New Drug Application To FDA For Zoryve® Foam
Arcutis rises on US FDA's expanded use nod for skin disease drug
Brief: US FDA Approves Arcutis' Zoryve To Treat Atopic Dermatitis In Patients 6 Years Of Age And Older
Arcutis rises as FDA approves expanded use of skin disease drug
Brief: Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
U.S. STOCKS ON THE MOVE-Dell, Biogen, Canoo
U.S. STOCKS ON THE MOVE-Nextracker, Arcutis Biotherapeutics, Nu Holdings
Drugmaker Arcutis jumps on rise in Q1 revenue
Arcutis Biotherapeutics Inc reports results for the quarter ended in March - Earnings Summary
Arcutis Biotherapeutics up after Q1 revenue rises
Arcutis Biotherapeutics Inc expected to post a loss of 73 cents a share - Earnings Preview